AIDS vaccine models: Challenging challenge viruses

Preclinical challenge studies of AIDS vaccines in non-human primates have an important role in the AIDS vaccine development effort. However, to be most useful, challenge models need to be improved to more closely reflect the actual biological circumstances of HIV-1 infection and transmission in humans.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Contrasting natural histories of AIDS virus infections.


  1. 1

    Nathanson, N., Hirsch, V.M. & Mathieson, B.J. The role of nonhuman primates in the development of an AIDS vaccine. AIDS 13 (suppl. A), S113–S120 (1999).

  2. 2

    Hirsch, V.M. & Lifson, J.D. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv. Pharmacol. 49, 437–477 (2000).

  3. 3

    Li, J.T. et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J. Virol. 69, 7061–7067 (1995).

  4. 4

    Kuwata, T. et al. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication. J. Gen. Virol. 76, 2181–2191 (1995).

  5. 5

    Joag, S.V. et al. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J. Virol. 70, 3189–3197 (1996).

  6. 6

    Reimann, K.A. et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70, 6922–6928 (1996).

  7. 7

    Parker, R.A, Regan, M.M. & Reimann, K.A. Variability of viral load in plasma of Rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: Implications for using nonhuman primate AIDS models to test vaccines and therapeutics. J. Virol. 75, 11234–11238 (2001).

  8. 8

    Schultz, A.M. & Bradac, J. The HIV vaccine pipeline, from clinical to phase III. AIDS 15 (suppl. 5), S127–S137 (2001).

  9. 9

    Mascola, J.R. & Nabel, G.J. Vaccines for the prevention of HIV-1 disease. Curr. Opin. Immunol. 13, 489–495 (2001).

  10. 10

    Mellors, J.W. et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126, 946–954 (1997).

  11. 11

    Quinn, T.C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342, 921–929 (2000).

  12. 12

    Etemad-Moghadam, B. et al. Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J. Virol. 75, 5646–5655 (2001).

  13. 13

    Barouch, D.H. et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75, 5151–5158 (2001).

  14. 14

    Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–491 (2000).

  15. 15

    Amara, R.R. et al. Control of mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74 (2001).

  16. 16

    Shiver, J. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335 (2002).

  17. 17

    Rose, N.F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539–549 (2001).

  18. 18

    Matano, T., Kano, M., Nakamura, H., Takeda, A. & Nagai, Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNAprime/Sendai virus vector boost regimen. J. Virol. 75, 11891–11896. (2001).

  19. 19

    Chen, X. et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nature Med. 7, 1225–1231 (2001).

  20. 20

    Michael, N.L. et al. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection—evidence for highly susceptible human hosts. J. Infect. Dis. 175, 1352–1359 (1997).

  21. 21

    Montagnier, L. et al. Human immunodeficiency virus infection and AIDS in a person with negative serology. J. Infect. Dis. 175, 955–959 (1997).

  22. 22

    Zhang, Y.-j. et al. Use of inhibitors to evaluate co-receptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74, 6893–6910 (2000).

  23. 23

    Schuitemaker, H. et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population J. Virol. 66, 1354–1360 (1992).

  24. 24

    McCune, J.M. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410, 974–979 (2001).

  25. 25

    Veazey, R.S., Marx, P.A. & Lackner, A.A. The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol. 22, 626–633 (2001).

  26. 26

    Harouse, J.M., Gettie, A., Tan, R.C., Blanchard, J. & Cheng-Mayer, C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284, 816–819 (1999).

  27. 27

    Rosenberg, E.S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523–526 (2000).

  28. 28

    Lori, F. et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 290, 1591–1593 (2000).

  29. 29

    Lifson, J.D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584–2593 (2000).

  30. 30

    Oxenius, A. et al. Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection. Eur. J. Immunol. 31, 3782–3788 (2001).

  31. 31

    Blancou, P. et al. The infiltration kinetics of simian immunodeficiency virus-specific T cells drawn to sites of high antigenic stimulation determines local in vivo viral escape. Proc. Natl. Acad. Sci. USA 98, 13237–13242 (2001).

  32. 32

    Montefiori, D.C. et al. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus. J. Virol. 72, 3427–3431 (1998).

  33. 33

    Ourmanov, I. et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74, 2740–2751 (2000).

  34. 34

    Seth, A. et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74, 2502–2509 (2000).

  35. 35

    Barouch, D.H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335–339 (2002).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading